Nikhil Narang, MD
Cardiovascular Disease · Evanston, ILNPI 1922362383
Payments from drug & device makers
Across 446 payments — averaging $256.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$42K
- Abbott$27K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$20K
- AstraZeneca$8K
- Alnylam Pharmaceuticals Inc.$5K
- Lilly USA, LLC$5K
- plus $8K from 21 others
What the payments were for
- Consulting fees$6,9406%
- Speaking & faculty fees$89,86079%
- Travel & lodging$4,3454%
- Food & beverage$13,18012%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 35 | $42,106 |
| Abbott | 292 | $26,985 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $19,654 |
| AstraZeneca | 17 | $7,715 |
| Alnylam Pharmaceuticals Inc. | 8 | $4,756 |
| Lilly USA, LLC | 6 | $4,680 |
| Amgen | 4 | $2,551 |
| Akcea Therapeutics, Inc. | 5 | $2,216 |
| ZOLL Circulation Inc | 1 | $1,350 |
| Abiomed | 7 | $566 |
| Medtronic(2 entities) | 12 | $414 |
| Novo Nordisk | 8 | $346 |
| Cvrx, Inc. | 7 | $331 |
| Pfizer | 3 | $167 |
| E.r. Squibb & Sons, L.L.C. | 2 | $118 |
| Novartis | 3 | $59 |
| Johnson & Johnson | 3 | $50 |
| United Therapeutics Corporation | 2 | $46 |
| Lexicon Pharmaceuticals, Inc. | 2 | $46 |
| Bridgebio Pharma, Inc. | 1 | $45 |
| Daxor Corporation | 1 | $34 |
| Endotronix, Inc. | 1 | $23 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Lantheus Medical Imaging, Inc. | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Terumo Medical Corporation | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$46,448
- LifeVest$19,500
- CARDIOMEMS$7,719
- WAINUA$7,494
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$5,931
- CardioMEMS HF System$3,461
- ONPATTRO$3,150
- 2ND GEN CENTRIMAG PRIMARY CONSOLE$2,700
- Corlanor$2,380
- TEGSEDI$2,000
- AMVUTTRA$1,410
- TherOx DS2 Console$1,350
- Catheter$1,350
- Downstream Cartridge$1,350
- HeartMate PHP$1,074
- HeartMate 3 Left Ventricular Dev$495
- Impella$459
- HeartWare HVAD$239
- CentriMag$217
- HeartMate 3 Left Ventricular Assist Device$137
How this compares
$114,344 in reported general payments places this provider in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 413 | $393,802 |
| EntrestoSacubitril/Valsartan | 353 | $324,502 |
| EliquisApixaban | 108 | $106,950 |
| FarxigaDapagliflozin Propanediol | 54 | $47,872 |
| WegovySemaglutide | 27 | $43,172 |
| XareltoRivaroxaban | 33 | $35,299 |
| VerquvoVericiguat | 23 | $28,519 |
| OzempicSemaglutide | 27 | $25,146 |
| BrilintaTicagrelor | 33 | $17,089 |
| Tacrolimus | 20 | $3,170 |
| Metoprolol Succinate | 217 | $2,935 |
| Torsemide | 81 | $2,637 |
| Spironolactone | 375 | $2,385 |
| Atorvastatin Calcium | 238 | $2,347 |
| Mycophenolate Mofetil | 14 | $2,270 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $42,106 | $393,802413 claims |
| NovartisEntresto | $59 | $324,502353 claims |
| PfizerEliquis | $167 | $106,950108 claims |
| Novo NordiskWegovy, Ozempic | $346 | $68,31754 claims |
| AstraZenecaFarxiga, Brilinta | $7,715 | $64,96187 claims |
| Johnson & JohnsonXarelto | $50 | $35,29933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Evanston
- Robert GordonEvanston$413K
- Amit PursnaniEvanston$367K
- Steven SmartEvanston$165K
- Benjamin LumicaoChicago$3.7M
- Paul CremerChicago$2.9M
- Lokesh ChandraHazel Crest$2.7M
- Steven LupovitchArlington Heights$2.6M
- Nitasha SarswatChicago$2M
- Alan BrownNaperville$1.5M
- Alexander AdlerPeoria$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.